813,116 Shares in Nkarta, Inc. (NASDAQ:NKTX) Acquired by Monaco Asset Management SAM

Key Points

• Monaco Asset Management SAM invested approximately $1.50 million in Nkarta, Inc., acquiring about 813,116 shares in the first quarter, increasing its stake to 1.15% of the company.
• A number of institutional investors, including CWM LLC and Cerity Partners LLC, have also increased their positions in Nkarta, contributing to a total of 80.54% of the company's stock being owned by institutional investors.
• Nikarta's stock closed at $2.06 with a market cap of $146.18 million and a projected -1.7 EPS for the current year, while analysts maintain an average rating of "Buy" and a target price of $14.33.

Monaco Asset Management SAM bought a new stake in Nkarta, Inc. (NASDAQ:NKTX - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 813,116 shares of the company's stock, valued at approximately $1,496,000. Monaco Asset Management SAM owned approximately 1.15% of Nkarta as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Thrivent Financial for Lutherans acquired a new stake in Nkarta in the 4th quarter valued at about $258,000. American Century Companies Inc. lifted its stake in Nkarta by 8.8% during the fourth quarter. American Century Companies Inc. now owns 90,952 shares of the company's stock valued at $226,000 after buying an additional 7,378 shares in the last quarter. Sei Investments Co. purchased a new stake in Nkarta during the fourth quarter valued at about $57,000. JPMorgan Chase & Co. lifted its stake in Nkarta by 138.7% during the fourth quarter. JPMorgan Chase & Co. now owns 2,537,922 shares of the company's stock valued at $6,319,000 after buying an additional 1,474,560 shares in the last quarter. Finally, Wellington Management Group LLP lifted its stake in Nkarta by 4.1% during the fourth quarter. Wellington Management Group LLP now owns 225,224 shares of the company's stock valued at $561,000 after buying an additional 8,883 shares in the last quarter. Institutional investors own 80.54% of the company's stock.

Analysts Set New Price Targets

NKTX has been the subject of a number of analyst reports. William Blair reaffirmed a "market perform" rating on shares of Nkarta in a research note on Thursday, May 15th. Needham & Company LLC reduced their price target on shares of Nkarta from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Thursday, May 15th. Finally, Mizuho reduced their price target on shares of Nkarta from $16.00 to $14.00 and set an "outperform" rating for the company in a research report on Tuesday, June 10th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $14.33.

Nkarta Price Performance

Shares of Nkarta stock traded down $0.05 during trading on Friday, hitting $2.12. 472,909 shares of the company were exchanged, compared to its average volume of 567,093. Nkarta, Inc. has a 1-year low of $1.31 and a 1-year high of $6.63. The firm has a market capitalization of $150.44 million, a P/E ratio of -1.40 and a beta of 0.72. The firm's fifty day moving average price is $1.87 and its 200 day moving average price is $1.91.

Nkarta (NASDAQ:NKTX - Get Free Report) last released its quarterly earnings data on Wednesday, May 14th. The company reported ($0.43) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.01. As a group, equities research analysts anticipate that Nkarta, Inc. will post -1.7 earnings per share for the current year.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.